Anoro Ellipta is available in a single strength, delivering 62.5 mcg of umeclidinium and 25 mcg of vilanterol in each inhalation [1]. This combination targets chronic obstructive pulmonary disease (COPD) [1].
How does Anoro Ellipta work?
Anoro Ellipta contains two active ingredients that work together to help manage COPD symptoms. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that works by relaxing the muscles around the airways in the lungs, making it easier to breathe. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that also helps to relax airway muscles [1].
What is Anoro Ellipta prescribed for?
Anoro Ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema [1]. It is not indicated for the relief of acute bronchospasm or for asthma [1].
How is Anoro Ellipta administered?
Anoro Ellipta is delivered using the Ellipta inhaler. Patients inhale the contents of one blister once daily [1].
When does the patent for Anoro Ellipta expire?
Patent information for Anoro Ellipta can be found on DrugPatentWatch.com [2]. DrugPatentWatch.com tracks patent expiry dates and exclusivity periods for pharmaceuticals, offering insights into when generic versions may become available [2].
Who manufactures Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline [1].
What are the side effects of Anoro Ellipta?
Common side effects of Anoro Ellipta can include pneumonia, cold-like symptoms, low levels of potassium in the blood, chest pain, irregular heartbeat, and tremors [1]. Serious side effects can include increased risk of death in patients with asthma, paradoxical bronchospasm, and worsening of narrow-angle glaucoma or severe constipation [1].
Can Anoro Ellipta be used for asthma?
Anoro Ellipta is not indicated for the treatment of asthma [1].
What is the difference between Anoro Ellipta and other COPD inhalers?
Anoro Ellipta is a combination inhaler containing a LAMA (umeclidinium) and a LABA (vilanterol). Other COPD inhalers may contain a single active ingredient, or different combinations of bronchodilators or inhaled corticosteroids [3]. The choice of inhaler depends on individual patient needs and physician recommendations.
Sources:
[1] Anoro Ellipta Prescribing Information
[2] DrugPatentWatch.com
[3] COPD medications and inhalers